Trial · NCT02408523
Results by group11
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 11 of 11
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to the Second Primary Generalized Tonic Clonic (PGTC) Seizure During the 24-week Treatment Period From Visit 2 (Week 0) to Visit 10 (Week 24) | Placebo (FAS) | 76 | events | ||
| Time to the Second Primary Generalized Tonic Clonic (PGTC) Seizure During the 24-week Treatment Period From Visit 2 (Week 0) to Visit 10 (Week 24) | Lacosamide (FAS) | 49 | events | ||
| Percentage of Participants With Seizure Freedom for Primary Generalized Tonic Clonic (PGTC) Seizures During the 24-week Treatment Period From Visit 2 (Week 0) to Visit 10 (Week 24) | Placebo (FAS) | 17.3 | 95% Confidence Interval 10.3 to 24.3 | percentage of participants | |
| Percentage of Participants With Seizure Freedom for Primary Generalized Tonic Clonic (PGTC) Seizures During the 24-week Treatment Period From Visit 2 (Week 0) to Visit 10 (Week 24) | Lacosamide (FAS) | 31.0 | 95% Confidence Interval 22.4 to 39.6 | percentage of participants | |
| Time to the First Primary Generalized Tonic Clonic (PGTC) Seizure During the Treatment Period From Visit 2 (Week 0) to Visit 10 (Week 24) | Placebo (FAS) | 97 | events | ||
| Time to the First Primary Generalized Tonic Clonic (PGTC) Seizure During the Treatment Period From Visit 2 (Week 0) to Visit 10 (Week 24) | Lacosamide (FAS) | 79 | events | ||
| Percentage of Participants With at Least One Adverse Event (AE) as Reported Spontaneously by the Subject and/or Caregiver or Observed by the Investigator | Placebo (SS) | 81.8 | percentage of participants | ||
| Percentage of Participants With at Least One Adverse Event (AE) as Reported Spontaneously by the Subject and/or Caregiver or Observed by the Investigator | Lacosamide (SS) | 82.6 | percentage of participants | ||
| Plasma Concentrations of Lacosamide | Lacosamide (SS) | Visit 5, Week 6 (Titration) | 8.610961 | Standard Deviation 3.705438 | ug/mL |
| Plasma Concentrations of Lacosamide | Lacosamide (SS) | Visit 10, Week 24 (Maintenance) | 8.074427 | Standard Deviation 3.948749 | ug/mL |
| Plasma Concentrations of Lacosamide | Lacosamide (SS) | Early Termination Visit | 8.138085 | Standard Deviation 4.913627 | ug/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02408523/results